AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06254261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06459440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Task oriented Training
Description: Group Task-Oriented Training for individuals with Down syndrome is an approach that focuses on improving specific skills and promoting social interaction through collaborative activities. This training method involves organizing individuals with Down syndrome into small groups to work on tasks that target various developmental areas, such as motor skills, communication, and socialization. The tasks are designed to be meaningful, engaging, and relevant to the participants' daily lives.
Study NCT06459440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Treatment
Description: 1.Week 1-2 : Foundation building (4 sessions per week) Gentle stretching exercises (20 minutes). Basic strengthening exercises (20 minutes) (26). Weeks 3-4: Balance and coordination (4 sessions per week ) Balance exercises and core stability (20 minutes). Coordination drills (20 minutes) (26). Weeks 5-6: Functional activities (4 sessions per week )~Incorporate functional activities into therapy (e.g., walking, reaching) (20 minutes)
Study NCT06352346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensatory brain game supporting Goal Management Training intervention
Description: o The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently outside the therapy session. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
Study NCT06502639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: theraplay program
Description: A play therapy method called thermaplay aids in children's development of stronger bonds and relationships with others. It emphasizes the parts of communication that are nonverbal. When it comes to giving cerebral palsy children with hand therapy that is both effective and motivating, fun approaches have been shown to be both successful and appealing.
Study NCT06502639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: conventional physical therapy program for like stretching and strengthening exercises, sponge ball exercises to the hand, and hand weight bearing exercises
Study NCT06138418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurotomy
Description: Surgical treatment of spastic foot
Study NCT05697224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: urinary micro RNA detection
Description: Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR_71a gene expression analysis MAPK-3 gene expression analysis
Study NCT06481462 — intervention group
Intervention type: PROCEDURE
Intervention: Intrathecal Morphine (ITM)
Description: morphine 100 mcg + 12.5 mg bupivacaine + 10 mcg fentanyl
Study NCT06481462 — intervention group
Intervention type: PROCEDURE
Intervention: Quadratus Lumborum II (QLB-II) Block
Description: 12.5 mg bupivacaine + 20 mcg fentanyl bilateral QLB block (posterior tip 2) 25 cc 0.25% bupivacaine
Study NCT05993442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimised kangaroo care
Description: The intervention of optimised KC implementation consists of two components. Component 1 defines the targeted StSC for optimised KC, while component 2 is the implementation support to put in place a tailored implementation strategy.,
Study NCT06293781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Web-based ACT
Description: ACT program delivered online
Study NCT06293781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual for major depressive disorder
Study NCT06293781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual for major depressive disorder
Study NCT05845749 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vosoritide Injection [Voxzogo]
Description: Vosoritide will be given via a once daily subcutaneous injection at a dose of 15 ug/kg/day, at approximately the same time each day when feasible. Vosoritide will be supplied to the subject as 0.4 mg vial, 0.56 mg vial or 1.2 mg vials to be reconstituted with sterile water up to 0.8 mg/mL or 2 mg/mL concentrations for injection. The volume to be administered (injection volume) will be based on the subject's body weight and the concentration of vosoritide. All supplies will be provided to the subject for home based administration after training at the study site.
Study NCT04689828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: administered intravenously once every 6 weeks (1 cycle) for 6 cycles
Study NCT04689828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
Study NCT04689828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-PSMA-11
Description: single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
Study NCT04689828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARDT
Description: administered orally on a continuous basis, as per package insert and guidelines
Study NCT04689828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive/best standard of care as defined by the local investigator
Study NCT04689828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: Best supportive/best standard of care as defined by the local investigator
Study NCT05009264 — intervention group
Intervention type: PROCEDURE
Intervention: OMT
Description: OMT will be performed on identified areas of trapezius trigger points
Study NCT06639334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasttrack pathway for THA/HE prosthesis reduction
Description: The purpose of this study is to design a fast-track pathway for patients referred to the University Hospital of Southern Denmark, Esbjerg, with high probability of having a dislocated hip prosthesis with the primary aim to reduce the time from arrival to reduction and the total hospitalization time.~The intervention is changed logistic and work pathways at the hospital that should reduce time to reduction significantly. For detailed description we refer to the uploaded protocol.
Study NCT06639334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pathway for THA/HE prosthesis reduction
Description: Standard treatment for a dislocated THA/HA at our institution is education in general anesthesia at the operating theater. For detailed description we refer to the uploaded protocol.
Study NCT05574062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study Phase: MiniMed 780G Auto Mode with G4S sensor
Description: Subjects will start using the MiniMed™ 780G system in Auto Mode with G4S sensor.
Study NCT05574062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Study Phase: MiniMed 780G Manual Mode with G4S sensor
Description: Subjects will start using the MiniMed™ 780G system in Manual Mode.
Study NCT05574062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuation phase: MiniMed 780G BLE 2.0 with DS5 sensor
Description: Subjects will start using the MiniMed 780G BLE 2.0 with DS5 sensor
Study NCT05574062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuation Phase MiniMed 780G Auto Mode with G4S sensor
Description: Subjects will start using the MiniMed™ 780G system in Auto Mode with G4S sensor.
Study NCT06354257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/LNG
Description: One dose of EE and LNG is administered on Day 1 of treatment period 1 and one dose of EE/LNG co-administered with GSK3036656 DL 2 is given on Day 15 of treatment period 3.
Study NCT06354257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656 Dose Level 1
Description: A loading dose of GSK3036656 with DL 1 is administered on Day 4 of treatment period 2.
Study NCT06354257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656 Dose Level 2
Description: One dose of GSK3036656 DL 2 is administered once a day from Day 5 to Day 14 of treatment period 2. In treatment period 3 a single dose of GSK3036656 DL 2 co-administered with EE/LNG is given on Day 15, then GSK3036656 DL 2 once a day from Day 16 to Day 17.
Study NCT06321809 — intervention group
Intervention type: BEHAVIORAL
Intervention: intensive lifestyle
Description: INTENSIVE LIFESTYLE INTERVENTIONS
Study NCT03965702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a decision support system on the EV1000 monitoring (AFM mode)
Description: The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical decision support system for fluid administration called AFM (assisted fluid management) Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
Study NCT03965702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual application of the GDFT protocol (standard of care)
Description: Manual application of a GDFT protocol to guide fluid administration. Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
Study NCT05901519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day
Study NCT06345534 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Questionnaire
Description: Patients will be asked to complete questionnaires at different times (before, during and after radiation) to evaluate which schedule gives the fewest side effects and the best quality of life.~The basic questionnaire and questionnaire about early side effects will be completed weekly up to 6 weeks after radiotherapy. The questionnaire about late side effects will be completed: after 6 months, 1 year, 2 years, 3 years, 4 years and 5 years.
Study NCT05451017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition
Description: a single dose of 1 mg AEF0117 in fed condition
Study NCT05451017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition
Description: a single dose of 1 mg AEF0117 in fasting condition
Study NCT05156450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone
Description: Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.
Study NCT04557423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-Based Education
Description: A previously evaluated educational intervention delivered in community settings. Includes culturally- and linguistically-appropriate materials.
Study NCT04557423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-Based Education
Description: A previously evaluated educational intervention delivered in community settings. Includes culturally- and linguistically-appropriate materials.
Study NCT04557423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Navigation to Screening
Description: Community health educators provide navigation assistance to access clinic-based cervical cancer screening.
Study NCT04557423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation to Screening
Description: Community health educators provide navigation assistance to access clinic-based cervical cancer screening.
Study NCT04557423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Self-Sampling
Description: An HPV self-sampling kit will be provided for home-based collection of cervical samples. Samples will be sent for analysis of HPV subtypes.
Study NCT05852431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection
Study NCT05852431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT06417931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education and counselling
Description: The pharmacist intervention was aimed at identifying and addressing barriers to treatment adherence through tailored strategies
Study NCT05814159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: sub cutaneous daily injection
Study NCT05814159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sub cutaneous daily injection
Study NCT06455904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training sessions
Description: The training program will be performed during 15 weeks, with one session per week.
Study NCT06291779 — intervention group
Intervention type: DEVICE
Intervention: Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
Description: * Collect urine from the patient to measure urinary hypoxia, xanthine concentration.~* Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC).~* After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents.~* Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample.
Study NCT04614532 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cognitive assessment
Description: global cognitive assessment :~* Mini Mental State~* Evaluation of manual laterality~* Hospital Anxiety and Depression scale~* 5 words of Dubois~* Trail Making Test~* short battery of the praxies~* neuropathic pain scale (DN4 in french)~* Analog Visual Scale for pain~* Fast Front End Efficiency Battery
Study NCT04614532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cold Pressor Test
Description: consists of the complete immersion of the participant's arm in a basin of cold water maintained at a temperature.~The test will be divided into two conditions (pain, no pain). In the first, the container will be filled with cold water. In the second, the water in the container will be at room temperature. The investigators will test each arm. During the immersion of the arm, participants will have to remain silent and remove their arm when the ordeal becomes too painful for the painful condition.~For the non-painful condition, the immersion time will be determined according to the results of the pre test.
Study NCT04614532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: digital sensor of Nociception Level Index
Description: placed on the contralateral index finger with the arm immersed in the tank to measure the variation of physiological parameters.
Study NCT05912608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative TAAAD-R
Description: Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
Study NCT05912608 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conservative TAAAD-R
Description: Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
Study NCT05912608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extensive TAAAD-R
Description: Patients who experienced dilatation of the sinuses of Valsalva >4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total hemiarch) or reimplantation of the innominate trunk only (partial hemiarch).
Study NCT05912608 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Extensive TAAAD-R
Description: Patients who experienced dilatation of the sinuses of Valsalva >4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total hemiarch) or reimplantation of the innominate trunk only (partial hemiarch).
Study NCT04716725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Given IV
Study NCT06335836 — intervention group
Intervention type: BEHAVIORAL
Intervention: social isolation
Description: social isolation (0≤LSNS-6≤12)
Study NCT05147506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CNRM DTx
Description: A mobile application intervention adapted from the CBT for Depression and CBT for TBI manuals.
Study NCT05147506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation Comparison
Description: A mobile application that consists of psychoeducational material regarding depression and brain injury.
Study NCT05246787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breastfeeding
Description: nonphamacological methods
Study NCT05246787 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Breastfeeding and Shotblocker
Description: combined Breastfeeding and Shotblocker device
Study NCT05246787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shotblocker
Description: it is a small plastic tool
Study NCT03745417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells
Description: Umbilical cord mesenchymal stem cells were infused intravenously at a dose of 2 million cells/kg.
Study NCT05612087 — intervention group
Intervention type: DEVICE
Intervention: Confocal laser endomicroscopy
Description: Confocal laser endomicroscopy at jejunum, duodenum and stomach
Study NCT06330350 — intervention group
Intervention type: OTHER
Intervention: Qualitative interview
Description: Gaining insight into the perspectives of patients with genodermatoses and their partners, and health care professionals concerning reproductive decision-making and counselling.
Study NCT06336031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood-injection-injury (BII) phobia stimuli
Description: 498 seconds of BII phobia-related images and videos will begin two-minutes prior to head-up tilt test, while in supine.
Study NCT06336031 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: neutral stimuli
Description: 498 seconds of neutral images and videos will begin two-minutes prior to head-up tilt test, while in supine.
Study NCT04716725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo PET
Study NCT04199026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given via microdevice
Study NCT04199026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given via microdevice